Drug Trial Radar · NCT03959527
Zoliflodacin in Uncomplicated Gonorrhoea
Last checked: Nov 20, 2026Latest source record: Oct 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,011
Actual
Start
Nov 6, 2019
Primary completion
Aug 30, 2023
Study completion Sep 18, 2023
Sponsor
- Lead sponsor
- Global Antibiotics Research and Development PartnershipAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a multi-center, open label, randomized controlled, non-inferiority phase III trial evaluating the safety and efficacy of a 3 g oral dose of zoliflodacin compared to a combination of a single intra-muscular 500 mg dose of ceftriaxone and a single 1 g oral dose of azithromycin for the treatment of uncomplicated gonorrhoea.
Conditions
- Gonorrhea
Interventions
zoliflodacinDrug
Dose: 3g, oral administration
ceftriaxoneDrug
Dose: 500mg, Intra-Muscular (IM) administration
azithromycinDrug
Dose: 1g, oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Microbiological Cure Rate for Zoliflodacin Compared to a Combination of a Single Dose of Ceftriaxone and Azithromycin.Time frame: Day 6 (+/- 2)
Locations
17 sites in 5 countries. Site status is shown where the registry gives one.
Jefferson County Department of Health
Birmingham, Alabama
University of Alabama at Birmingham
Birmingham, Alabama
San Francisco Department Of Public Health City Clinic
San Francisco, California
Bell Flower Clinic
Indianapolis, Indiana
Louisiana State University Health Sciences Center
New Orleans, Louisiana
Public Health - Seattle & King County STD Clinic
Seattle, Washington
Institute of Tropical Medicine
Antwerp, Belgium
Public Health Service (GGD) Amsterdam / STI Outpatient Clinic
Amsterdam, Netherlands
SAMRC Botha's Hill Clinical Research Site
Bothas Hill, South Africa
Masiphumelele Research Site
Cape Town, South Africa
Ndlovu Research Centre
Elandsdoorn, South Africa
Wits RHI
Johannesburg, South Africa
Setshaba Research Centre
Soshanguve, South Africa
SAMRC Tongaat Clinical Research Site
Tongaat, South Africa
Bangrak STI Center
Bangkok, Thailand
Institute of HIV Research and Innovation
Bangkok, Thailand
Silom Community Clinic
Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.